{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:40:32Z","timestamp":1778625632686,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.clml.2019.08.012","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T22:59:54Z","timestamp":1568847594000},"page":"168-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma"],"prefix":"10.1016","volume":"20","author":[{"given":"Donald C.","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Tanner","family":"Ringley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala\u2019a","family":"Muslimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.08.012_bib1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.08.012_bib2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.08.012_bib3","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib, and dexamethasone as induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.08.012_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.012_bib5","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction therapy prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma","volume":"28","author":"Harousseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.08.012_bib6","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.012_bib7","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cncr.22921","article-title":"Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature","volume":"110","author":"Badros","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.08.012_bib8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3816\/CLM.2008.n.017","article-title":"Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma","volume":"8","author":"El-Cheikh","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2019.08.012_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.leukres.2009.07.022","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients","volume":"34","author":"Corso","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.08.012_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.08.012_bib11","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.7314\/APJCP.2015.16.17.7603","article-title":"Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran","volume":"16","author":"Shahriari-Ahmadi","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clml.2019.08.012_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000442527","article-title":"Diabetes and body mass index are associated with neuropathy and prognosis in colon cancer patients treated with capecitabine and oxaliplatin adjuvant chemotherapy","volume":"90","author":"Ottaiano","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2019.08.012_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw206","article-title":"BMI, lifestyle factors, and taxane-induced neuropathy in breast cancer patients: the Pathways Study","volume":"109","author":"Greenlee","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2019.08.012_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejpain.2009.07.001","article-title":"Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological, and pathological study in rats","volume":"14","author":"Meregalli","year":"2010","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clml.2019.08.012_bib15","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Pei","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.08.012_bib16","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed patients with multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.012_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FPC.0b013e3283436b45","article-title":"Genetic variation associated with bortezomib-induced peripheral neuropathy","volume":"21","author":"Favis","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clml.2019.08.012_bib18","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3324\/haematol.2011.041434","article-title":"Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients","volume":"96","author":"Corthals","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.08.012_bib19","first-page":"5436","article-title":"Impact of race on bortezomib-induced peripheral neuropathy","volume":"130","author":"Cheung","year":"2017","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019313825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019313825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:35:16Z","timestamp":1730529316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019313825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S2152265019313825"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.08.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}